Widely used:Recently Viewed
Clear All
$10.31
$-0.34
(-3.19%)
As on 17-Apr-2025 16:15EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$1,321 Mln
P/E Ratio
53.25
P/B Ratio
2.37
Industry P/E
--
Debt to Equity
0.42
ROE
0.04 %
ROCE
3.16 %
Div. Yield
0 %
Book Value
3.9
EPS
0.18
CFO
$-196.86 Mln
EBITDA
$-262.92 Mln
Net Profit
$-443.71 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Dynavax Technologies (DVAX)
| -19.26 | -25.67 | -16.79 | -10.27 | -0.64 | 25.14 | -8.16 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Dynavax Technologies (DVAX)
| -8.59 | 31.39 | -24.38 | 216.18 | -22.20 | -37.49 | -50.88 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of... infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California. Address: 2100 Powell Street, EmeryVille, CA, United States, 94608 Read more
CEO, Interim CFO & Director
Mr. Ryan Spencer
CEO & Director
Mr. Ryan Spencer
Headquarters
EmeryVille, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Dynavax Technologies Corporation (DVAX) stood at $ 986 Mln as on 31-Dec-24
The share price of Dynavax Technologies Corporation (DVAX) is $10.31 (NASDAQ) as of 17-Apr-2025 16:15 EDT. Dynavax Technologies Corporation (DVAX) has given a return of -0.64% in the last 3 years.
Dynavax Technologies Corporation (DVAX) has a market capitalisation of $ 1,321 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Dynavax Technologies Corporation (DVAX) is 53.25 times as on 17-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Dynavax Technologies Corporation (DVAX) and enter the required number of quantities and click on buy to purchase the shares of Dynavax Technologies Corporation (DVAX).
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California. Address: 2100 Powell Street, EmeryVille, CA, United States, 94608
The CEO & director of Mr. Ryan Spencer. is Dynavax Technologies Corporation (DVAX), and CFO & Sr. VP is Mr. Ryan Spencer.
There is no promoter pledging in Dynavax Technologies Corporation (DVAX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,031
|
|
|
989
|
|
|
950
|
|
|
915
|
| Dynavax Technologies Corporation (DVAX) | Ratios |
|---|---|
|
Return on equity(%)
|
4.48
|
|
Operating margin(%)
|
13.58
|
|
Net Margin(%)
|
9.85
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Dynavax Technologies Corporation (DVAX) was $0 Mln.
